GEN Exclusives

More »

Corporate Profiles

More »
Feb 1, 2009 (Vol. 29, No. 3)

CytImmune Banks on Gold Nanoparticles

Clinical-Stage Firm Delivers TNF-α to Tumors with Proprietary Colloidal Gold System

  • Lead Compound

    Aurimune™ (CYT-6091), the company’s lead drug compound, simultaneously binds PEG-Thiol and recombinant TNF-α to colloidal gold nanoparticles. The result is an anticancer agent that is invisible to immediate immune detection, thereby avoiding uptake by the liver and spleen, and targeting delivery of TNF-α directly to tumor sites at acceptable toxicity levels, Dr. Tamarkin says. 

    “Each element serves a unique purpose,” he adds. The colloidal gold limits the distribution of the TNF-α, so that every nanoparticle exerts its bioactivity in the right place. PEGylation—treatment with polyethylene glycol masks the colloidal gold particles from immediate immune recognition and primarily prevents uptake in areas of the body other than tumors.

    The PEG-Thiol hydrates each nanoparticle of gold. At 27 nanometers, the gold particles are small enough to traffic safely through the body, but too big to exit through the circulation system. Thus, Aurimune “primarily and preferentially exits the circulation through leaky, newly formed vasculature at tumor sites, selectively passing through gaps in blood vessel walls called fenestrations,” according to Dr. Tamarkin.

    “The ideal cancer nanomedicine is built like a three-legged stool,” he says. “By design, it avoids uptake by the liver and the spleen.  By design, it targets tumors in two ways—passively through leaky blood vessels and actively by binding to tumor-associated receptors like those on endothelial cells. Finally, nanomedicines must be manufactured to defined specifications by a process that is simple, robust, characterizable, and cost-effective.

    Because Aurimune attacks blood vessels that support solid tumor growth, it may be used in combination with chemotherapies and improve overall efficiency, explains Dr. Tamarkin. “By pretreating a patient with Aurimune, clinicians may destroy intra-tumor pressure gradients, causing a leak in the tumor vasculature and allowing subsequent chemotherapies to work more effectively. We believe we can systemically deliver Aurimune and follow it with chemotherapy, potentially offering better results than either treatment alone.”

    Recently completed Phase I trials of Aurimune, conducted at and by the NCI, showed that the drug was well tolerated, with no drug-related serious adverse events, despite treatment with doses far exceeding the previously established maximally tolerated dose for TNF-α alone,  while showing gold nanoparticles at tumor sites. Data demonstrated that Aurimune safely and systematically delivered TNF-α  in humans far beyond concentrations attained in previous studies—and in an amount equal to that used in ILP where 60–85% cancer response rates have been observed, Dr. Tamarkin reports.

    Slated to begin in 2009, the Aurimune Phase II clinical protocol is designed to mimic the ILP protocol. Combining Aurimune with chemotherapy, these studies will treat pancreatic cancer, melanoma, soft tissue sarcoma, ovarian, breast, and non-small-cell lung cancer patients.

    AuriTol, another nanomedicine under development by CytImmune, is currently in preclinical development. It is based on a formulation of an analog of paclitaxel and TNF-α bound to CytImmune’s nanoparticle. This formulation has the potential to offer improved efficacy and a reduction of side effects relative to current forms of paclitaxel, according to Dr. Tamarkin. AuriTol Phase I trials may begin in early 2010.

    In addition, CytImmune has developed a method to generate fully human monoclonal antibodies using lymphocytes from normal donors. The technology uses the properties of gold nanoparticles to create an antigen presentation system that loosely mimics the natural presentation of antigens by cells. CytImmune has begun proof-of-principle studies with antibodies against multiple components of the interleukin-2 receptor to block the production of T-cells for the treatment of leukemia and lymphoma.

    “Our goal is to suppress the growth of cancer cells by disrupting the blood vessels that support cancer growth, and thus keep cancer at bay with a less invasive, less traumatic procedure,” Dr. Tamarkin concludes. “Cancer should be a chronic illness, not a death sentence.”



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?